Novo Nordisk Faces Mounting Challenges on Pricing and Pipeline
Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug,…
Novo Nordisk Faces Mounting Pressure as Generic Rival Emerges
The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already…
Novo Nordisk Faces Manufacturing Push and Regulatory Scrutiny
The Danish pharmaceutical giant Novo Nordisk is navigating a complex landscape as it seeks to expand production for…
Novo Nordisk Faces Dual FDA Scrutiny and Legal Battles Over Obesity Drugs
Trump Administration Pushes Back on UN Climate Proposal Global climate diplomacy has entered another tense chapter. The administration…